BC Extra | Apr 5, 2019
Politics & Policy

DOJ releases details on biopharma settlements for alleged kickbacks to co-pay charities

Alexion has been added to the list of biopharma companies that have settled allegations of kickbacks to charitable patient assistance programs, according to a Department of Justice statement released Thursday. United Therapeutics Corp. (NASDAQ:UTHR), Actelion...
BC Week In Review | Dec 15, 2017
Company News

Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) disclosed details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%, to 39,000 over the next two years. Teva expects the cuts,...
BC Extra | Dec 14, 2017
Company News

Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) gained $1.60 (10%) to $17.30 in New York on Thursday after disclosing details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%,...
BC Extra | Nov 22, 2017
Politics & Policy

ICER says price of tardive dyskinesia drugs far exceed benefit

In an evidence report released Tuesday, the Institute for Clinical and Economic Review said the prices of tardive dyskinesia drugs Ingrezza valbenazine and Austedo deutetrabenazine need to be discounted by about 90% to align with...
BC Week In Review | Oct 6, 2017
Clinical News

FDA approves Teva's Austedo for tardive dyskinesia

FDA approved Austedo deutetrabenazine (SD-809) from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to treat tardive dyskinesia in adults. Austedo is already approved in the U.S. to treat chorea associated with Huntington’s disease (HD). The...
BC Extra | Apr 26, 2017
Company News

Neurocrine prices Ingrezza

Neurocrine Biosciences Inc. (NASDAQ:NBIX) priced tardive dyskinesia therapy Ingrezza valbenazine at a wholesale acquisition cost (WAC) of $5,275 for a 30-count bottle of 40 mg capsules. At FDA-recommended dosing, the drug's annual cost is more...
BC Extra | Apr 21, 2017
Politics & Policy

ICER to assess tardive dyskinesia drugs

The Institute for Clinical Effectiveness and Economic Review said it will review the comparative clinical effectiveness and value of tardive dyskinesia compounds in an upcoming report to be published late this year. ICER said it...
BioCentury | Apr 15, 2017
Strategy

WAC-a-mol

While investors, media and even some payers have been touting the pricing of three recently launched drugs as sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But...
BC Week In Review | Apr 14, 2017
Clinical News

Austedo regulatory update

FDA approved Austedo deutetrabenazine from Teva to treat chorea associated with Huntington’s disease (HD). Teva said the drug is the second FDA has approved for HD, and the first deuterated therapy. The company expects to...
BC Extra | Apr 12, 2017
Financial News

Neurocrine climbs on Ingrezza approval

Neurocrine Biosciences Inc. (NASDAQ:NBIX) rose $10.32 (25%) to $51.80 on Wednesday, adding about $900 million in market cap, after FDA approved its Ingrezza valbenazine to treat tardive dyskinesia. The approval, the first in the indication,...
Items per page:
1 - 10 of 122